Form 4: Amylyx Pharmaceuticals Director Acquires Stock Options

Daphne Quimi, a Director at Amylyx Pharmaceuticals, acquired 24,372 stock options with an exercise price of $14.31 on June 4, 2026.

Summary

• Director Daphne Quimi acquired 24,372 stock options on June 4, 2026.
• The exercise price for these options is $14.31.
• These options are set to expire on June 3, 2036.
• The shares subject to the option will fully vest on June 4, 2027, or the next annual meeting, provided Quimi remains in continuous service.
• This transaction is filed under Rule 10b5-1(c) for the purchase of equity securities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard stock option grant to a director, indicating potential future upside but not immediate financial impact.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The acquisition of options at a specific exercise price indicates a potential future value appreciation for the company's stock.

Risks

• The vesting schedule for the stock options is contingent on the Reporting Person's continuous service to the Issuer, meaning any departure before the vesting date would result in forfeiture of the options.
• The value of the acquired options is directly tied to the future performance and stock price of Amylyx Pharmaceuticals.

Future Outlook

The acquisition of stock options by a director suggests a positive outlook on the company's future stock performance, as the options will only be valuable if the stock price exceeds the exercise price of $14.31.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the biopharmaceutical industry, often used as a long-term incentive to align management's interests with those of shareholders and to retain key talent.

Stakeholder Impact

• Shareholders: The acquisition of options by a director may be viewed positively as it aligns management's interests with long-term shareholder value, provided the company's stock performs well.
• Employees: The vesting condition tied to continuous service reinforces the importance of employee retention for the company's operational stability and future growth.

Next Steps

• The shares subject to the option will vest in full on June 4, 2027, or the date of the next annual meeting, contingent on continuous service.
• The options are exercisable until their expiration date of June 3, 2036.

Key Dates

Keywords

Amylyx Pharmaceuticals, AMLX, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing, Equity Securities, Rule 10b5-1(c)